{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:53:48Z","timestamp":1790736828523,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.modpat.2026.100963","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:23:43Z","timestamp":1769127823000},"page":"100963","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Worldwide Survey on Pathological Measurement of Residual Breast Cancer After Neoadjuvant Therapy: Different Interpretations of the ypTNM Classification"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7450-4047","authenticated-orcid":false,"given":"Koen","family":"Kwakkenbos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieke R.","family":"Van Bockstal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer M.","family":"Shaaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edi","family":"Brogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabor","family":"Cserni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian O.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Foschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Bago-Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabnam","family":"Jaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Pinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Provenzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecily M.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad A.","family":"Rakha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy A.","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puay Hoon","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary M.","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah Y.","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolien H.M.","family":"van Deurzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9938","key":"10.1016\/j.modpat.2026.100963_bib1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.modpat.2026.100963_bib2","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1200\/JCO.22.02241","article-title":"Pathologic complete response and individual patient prognosis after neoadjuvant chemotherapy plus anti-human epidermal growth factor receptor 2 therapy of human epidermal growth factor receptor 2-positive early breast cancer","volume":"41","author":"van Mackelenbergh","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.modpat.2026.100963_bib3","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","article-title":"Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis","volume":"26","author":"Spring","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.modpat.2026.100963_bib4","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaoncol.2020.2535","article-title":"Association of event-free and distant recurrence-free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-SPY2 adaptively randomized clinical trial","volume":"6","author":"Yee","year":"2020","journal-title":"JAMA Oncol"},{"issue":"22","key":"10.1016\/j.modpat.2026.100963_bib5","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.modpat.2026.100963_bib6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMoa2406070","article-title":"Survival with trastuzumab emtansine in residual HER2-positive breast cancer","volume":"392","author":"Geyer","year":"2025","journal-title":"N Engl J Med"},{"issue":"28","key":"10.1016\/j.modpat.2026.100963_bib7","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2026.100963_bib8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","article-title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.modpat.2026.100963_bib9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3857\/roj.2024.00087","article-title":"Oncological outcomes in patients with residual triple-negative breast cancer after preoperative chemotherapy","volume":"42","author":"Park","year":"2024","journal-title":"Radiat Oncol J"},{"issue":"5","key":"10.1016\/j.modpat.2026.100963_bib10","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.annonc.2024.02.002","article-title":"Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522","volume":"35","author":"Pusztai","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.modpat.2026.100963_bib11","series-title":"TNM Classification of Malignant Tumours","author":"Brierley","year":"2017"},{"key":"10.1016\/j.modpat.2026.100963_bib12","series-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"issue":"7","key":"10.1016\/j.modpat.2026.100963_bib13","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/his.15165","article-title":"A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR)","volume":"84","author":"Bossuyt","year":"2024","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.modpat.2026.100963_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13058-024-01781-1","article-title":"MRI-based tumor shrinkage patterns after early neoadjuvant therapy in breast cancer: correlation with molecular subtypes and pathological response after therapy","volume":"26","author":"Wang","year":"2024","journal-title":"Breast Cancer Res"},{"issue":"5","key":"10.1016\/j.modpat.2026.100963_bib15","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/s41379-020-00714-5","article-title":"Clinico-pathologic predictors of patterns of residual disease following neoadjuvant chemotherapy for breast cancer","volume":"34","author":"Pastorello","year":"2021","journal-title":"Mod Pathol"},{"issue":"12","key":"10.1016\/j.modpat.2026.100963_bib16","doi-asserted-by":"crossref","first-page":"7726","DOI":"10.1245\/s10434-022-12054-6","article-title":"Impact of the histologic pattern of residual tumor after neoadjuvant chemotherapy on recurrence and survival in stage I-III breast cancer","volume":"29","author":"Laws","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.modpat.2026.100963_bib17","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/his.14966","article-title":"Pathological measurement and staging of residual breast cancer after neoadjuvant chemotherapy","volume":"83","author":"Harter","year":"2023","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.modpat.2026.100963_bib20","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/his.15191","article-title":"Dataset for reporting of the invasive carcinoma of the breast: recommendations from the International Collaboration on Cancer Reporting (ICCR)","volume":"85","author":"Ellis","year":"2024","journal-title":"Histopathology"},{"issue":"8","key":"10.1016\/j.modpat.2026.100963_bib21","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/cncr.24173","article-title":"Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer","volume":"115","author":"Loya","year":"2009","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.modpat.2026.100963_bib22","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/his.15417","article-title":"The prevalence and clinical significance of residual occult breast cancer after neoadjuvant chemotherapy: reassessing surgical pathology in cases initially described as pathological complete response","volume":"86","author":"Ai","year":"2025","journal-title":"Histopathology"},{"issue":"11","key":"10.1016\/j.modpat.2026.100963_bib23","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1245\/s10434-019-07517-2","article-title":"Prognostic significance of residual axillary nodal micrometastases and isolated tumor cells after neoadjuvant chemotherapy for breast cancer","volume":"26","author":"Wong","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.modpat.2026.100963_bib24","series-title":"TNM Classification of Malignant Tumours","author":"Brierley","year":"2025"},{"issue":"8","key":"10.1016\/j.modpat.2026.100963_bib25","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.crad.2018.01.005","article-title":"The importance of histological assessment after neoadjuvant therapy and the need for standardisation","volume":"73","author":"Naidoo","year":"2018","journal-title":"Clin Radiol"},{"issue":"7","key":"10.1016\/j.modpat.2026.100963_bib26","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/annonc\/mdv161","article-title":"Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration","volume":"26","author":"Bossuyt","year":"2015","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.modpat.2026.100963_bib27","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/modpathol.2015.74","article-title":"Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group","volume":"28","author":"Provenzano","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.modpat.2026.100963_bib28","article-title":"Improved prediction of survival outcomes using residual cancer burden in combination with Ki-67 in breast cancer patients underwent neoadjuvant chemotherapy","volume":"12","author":"Kim","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2026.100963_bib29","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-017-4303-8","article-title":"Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007\/150012; ACRIN 6657)","volume":"165","author":"Campbell","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"10.1016\/j.modpat.2026.100963_bib30","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/1759-7714.14826","article-title":"Good practice: the experiences with the utilization of residual cancer burden-a single institution study","volume":"14","author":"Sejben","year":"2023","journal-title":"Thorac Cancer"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226000062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226000062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T02:41:25Z","timestamp":1775788885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395226000062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0893395226000062"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2026.100963","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Worldwide Survey on Pathological Measurement of Residual Breast Cancer After Neoadjuvant Therapy: Different Interpretations of the ypTNM Classification","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2026.100963","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}],"article-number":"100963"}}